TY - JOUR
T1 - RNA and imidazoquinolines are sensed by distinct TLR7/8 ectodomain sites resulting in functionally disparate signaling events
AU - Colak, Elif
AU - Leslie, Alasdair
AU - Zausmer, Kieran
AU - Khatamzas, Elham
AU - Kubarenko, Andriy V.
AU - Pichulik, Tica
AU - Klimosch, Sascha N.
AU - Mayer, Alice
AU - Siggs, Owen
AU - Hector, Andreas
AU - Fischer, Roman
AU - Klesser, Benedikt
AU - Rautanen, Anna
AU - Frank, Martin
AU - Hill, Adrian V.S.
AU - Manoury, Bélnéldicte
AU - Beutler, Bruce
AU - Hartl, Dominik
AU - Simmons, Alison
AU - Weber, Alexander N.R.
PY - 2014/6/15
Y1 - 2014/6/15
N2 - TLRs 7 and 8 are pattern recognition receptors controlling antiviral host defense or autoimmune diseases. Apart from foreign and host RNA, synthetic RNA oligoribonucleotides (ORN) or small molecules of the imidazoquinoline family activate TLR7 and 8 and are being developed as therapeutic agonists. The structure-function relationships for RNA ORN and imidazoquinoline sensing and consequent downstream signaling by human TLR7 and TLR8 are unknown. Proteome- and genome-wide analyses in primary human monocyte-derived dendritic cells here showed that TLR8 sensing of RNA ORN versus imidazoquinoline translates to ligand-specific differential phosphorylation and transcriptional events. In addition, TLR7 and 8 ectodomains were found to discriminate between RNA ORN and imidazoquinolines by overlapping and nonoverlapping recognition sites to which murine lossoffunction mutations and human naturally occurring hyporesponsive polymorphisms map. Our data suggest TLR7 and TLR8 can signal in two different "modes" depending on the class of ligand. Considering RNA ORN and imidazoquinolines have been regarded as functionally interchangeable, our study highlights important functional incongruities whose understanding will be important for developing TLR7 or 8 therapeutics with desirable effector and safety profiles for in vivo application.
AB - TLRs 7 and 8 are pattern recognition receptors controlling antiviral host defense or autoimmune diseases. Apart from foreign and host RNA, synthetic RNA oligoribonucleotides (ORN) or small molecules of the imidazoquinoline family activate TLR7 and 8 and are being developed as therapeutic agonists. The structure-function relationships for RNA ORN and imidazoquinoline sensing and consequent downstream signaling by human TLR7 and TLR8 are unknown. Proteome- and genome-wide analyses in primary human monocyte-derived dendritic cells here showed that TLR8 sensing of RNA ORN versus imidazoquinoline translates to ligand-specific differential phosphorylation and transcriptional events. In addition, TLR7 and 8 ectodomains were found to discriminate between RNA ORN and imidazoquinolines by overlapping and nonoverlapping recognition sites to which murine lossoffunction mutations and human naturally occurring hyporesponsive polymorphisms map. Our data suggest TLR7 and TLR8 can signal in two different "modes" depending on the class of ligand. Considering RNA ORN and imidazoquinolines have been regarded as functionally interchangeable, our study highlights important functional incongruities whose understanding will be important for developing TLR7 or 8 therapeutics with desirable effector and safety profiles for in vivo application.
UR - http://www.scopus.com/inward/record.url?scp=84902123849&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.1303058
DO - 10.4049/jimmunol.1303058
M3 - Article
C2 - 24813206
AN - SCOPUS:84902123849
SN - 0022-1767
VL - 192
SP - 5963
EP - 5973
JO - Journal of Immunology
JF - Journal of Immunology
IS - 12
ER -